These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25264941)
21. The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities. Hoffman KL; Foster EA; Smith CL Steroids; 2012 Apr; 77(5):496-503. PubMed ID: 22326682 [TBL] [Abstract][Full Text] [Related]
22. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945 [TBL] [Abstract][Full Text] [Related]
23. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440 [TBL] [Abstract][Full Text] [Related]
24. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells. Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806 [TBL] [Abstract][Full Text] [Related]
25. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α. Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700 [TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. Laïos I; Journe F; Laurent G; Nonclercq D; Toillon RA; Seo HS; Leclercq G J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):207-21. PubMed ID: 14672741 [TBL] [Abstract][Full Text] [Related]
28. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981 [TBL] [Abstract][Full Text] [Related]
29. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652 [TBL] [Abstract][Full Text] [Related]
30. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885 [TBL] [Abstract][Full Text] [Related]
31. Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis. Marchese S; Silva E PLoS One; 2012; 7(10):e45767. PubMed ID: 23056216 [TBL] [Abstract][Full Text] [Related]
32. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. Sreeja S; Santhosh Kumar TR; Lakshmi BS; Sreeja S J Nutr Biochem; 2012 Jul; 23(7):725-32. PubMed ID: 21839626 [TBL] [Abstract][Full Text] [Related]
33. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965 [TBL] [Abstract][Full Text] [Related]
34. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells. Fortunati N; Bertino S; Costantino L; De Bortoli M; Compagnone A; Bandino A; Catalano MG; Boccuzzi G Mol Cell Endocrinol; 2010 Jan; 314(1):17-22. PubMed ID: 19772891 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor. Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419 [TBL] [Abstract][Full Text] [Related]
36. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Katzenellenbogen BS; Montano MM; Ekena K; Herman ME; McInerney EM Breast Cancer Res Treat; 1997 May; 44(1):23-38. PubMed ID: 9164675 [TBL] [Abstract][Full Text] [Related]
37. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561 [TBL] [Abstract][Full Text] [Related]
38. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. Pearce ST; Liu H; Jordan VC J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244 [TBL] [Abstract][Full Text] [Related]
39. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366 [TBL] [Abstract][Full Text] [Related]
40. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]